Drug Trial Radar · NCT06369012
Management of Abnormal Uterine Bleeding
Last checked: Nov 20, 2026Latest source record: Sep 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
130
Actual
Start
Mar 1, 2024
Primary completion
Sep 1, 2024
Study completion Sep 30, 2024
Sponsor
- Lead sponsor
- EgymedicalpediaIndustry
- Sponsor type
- Industry
- First posted
- Apr 16, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 15 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Abnormal uterine bleeding "AUB" describes all abnormal forms of menstrual bleeding which may result from several causes including anovulation, problems related to pregnancy, infections, vaginal and cervical abnormalities, uterine pathologies including benign and malignant tumors, coagulopathies, endocrine disorders, trauma, foreign bodies, systemic diseases and iatrogenic causes. AUB may be clinically presented by menorrhagia, metrorrhagia or menometrorrhagia. It's the most common complaint for the reproductive age females and accounts for 33% of female patients referred to gynecologists
Conditions
- Abnormal Uterine Bleeding
Interventions
Mefenamic acid 500 mgDrug
To compare the effectiveness of mefenamic acid versus tranexamic acid in the management of abnormal uterine bleeding.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Bleeding ControlTime frame: 1 week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ain Shams University Hospitals
Cairo, Egypt
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.